Welcome to our dedicated page for National Vision SEC filings (Ticker: EYE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for National Vision Holdings, Inc. (NASDAQ: EYE), a Delaware-incorporated optical retail company. As a Nasdaq-listed issuer, National Vision files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with other required documents. These filings offer detailed information on the company’s financial condition, risk factors, governance, and material events.
National Vision’s Form 8-K filings have covered topics such as quarterly financial results, amendments to material agreements, annual meeting voting outcomes, and changes in directors and executive officers. For example, recent 8-Ks have reported results of operations and financial condition, board and leadership changes, and an amendment to a letter agreement with a key business partner. These documents help investors track developments that the company deems material.
In its SEC reports, National Vision discusses its optical retail operations, including its store footprint, brand portfolio, and operating segments, as well as non-GAAP financial measures like Adjusted Operating Income, Adjusted Operating Margin, Adjusted Diluted EPS, and Adjusted Comparable Store Sales Growth. The filings describe how these measures are defined and reconciled to GAAP, and outline the risks and uncertainties that could affect future performance, such as competition, macroeconomic conditions, technology investments, regulatory compliance, and vendor relationships.
On Stock Titan, National Vision’s filings are updated as they are released on EDGAR, and AI-powered summaries can help explain the key points in lengthy documents such as 10-K and 10-Q reports or detailed 8-K disclosures. Users can also review information related to governance matters, executive and director changes, and other regulatory disclosures associated with the EYE ticker.
National Vision Holdings, Inc. is asking stockholders to vote at its 2026 annual meeting on June 17, 2026, on three items: electing eleven directors, approving executive pay on an advisory basis, and ratifying Deloitte & Touche LLP as auditor.
The proxy highlights 2025 as a transformational year, with comparable store sales growth of 5.9% (6.0% adjusted), net revenue rising 9.0% to $1,987.5 million, and net income from continuing operations of $29.6 million, or diluted EPS of $0.37. Adjusted operating income from continuing operations increased to $102.5 million from $65.5 million, and adjusted diluted EPS reached $0.80. The company ended 2025 with 1,250 stores, a cash balance of $38.7 million, total liquidity of $332 million, and net debt of $245.9 million after repaying $101.3 million of long-term debt and convertible notes.
Governance updates include completion of CEO succession, with Alex Wilkes becoming CEO and director and former CEO L. Reade Fahs serving as Executive Chairman, alongside a Lead Independent Director and a majority-independent, diverse board. The compensation program emphasizes pay-for-performance, using annual incentives tied mainly to adjusted operating income and long-term equity split between time-based RSUs and PSUs based on adjusted operating income, return on invested capital, and relative total shareholder return, with a special 2026 PSU design adding a stock-price-based modifier.
National Vision Holdings Chief Legal & Strategy Officer Jared Brandman reported routine equity compensation activity involving restricted stock units. On April 29, 2026, 1,890 restricted stock units vested and converted into common stock on a one-for-one basis. To cover associated tax liabilities, 842 common shares were withheld and disposed of at $22.39 per share, resulting in a net increase of 1,048 common shares. Following these transactions, Brandman directly holds 77,079 shares of common stock and 36,744 remaining restricted stock units, reflecting ongoing equity-based compensation rather than open-market trading.
Vanguard Capital Management reports beneficial ownership of 4,020,142 shares (5.06%) of National Vision Holdings Inc as of 03/31/2026. The filing shows sole voting power for 582,275 shares and sole dispositive power for 4,020,142 shares. The disclosure states these holdings include securities managed across Vanguard affiliates and funds.
The filing is signed by Ashley Grim, Head of Global Fund Administration, on 04/30/2026 and lists Vanguard's Malvern, PA business address.
National Vision Holdings Inc reports that Vanguard Portfolio Management beneficially owns 5,781,797 shares of common stock, representing 7.27% as of 03/31/2026. The filing shows sole voting power of 34,814 shares and sole dispositive power over 5,781,797 shares. The filing is signed on 04/29/2026.
National Vision Holdings, Inc. Chief Financial Officer Christopher Laden exercised restricted stock units that vested into common stock and used part of the shares to cover taxes. On March 31, 2026, 26,082 restricted stock units converted into 26,082 shares of common stock on a one-for-one basis.
To satisfy tax liabilities tied to this vesting, 9,702 shares were withheld at a price of $25.90 per share, leaving 16,380 shares of common stock directly held after the withholding. Following the conversion, Laden also held 70,088 restricted stock units, which continue to represent future potential shares as they vest.
The Vanguard Group filed an amendment to its Schedule 13G/A reporting for National Vision Holdings Inc. The amendment states Amount beneficially owned: 0 and Percent of class: 0%. It explains an internal realignment effective January 12, 2026 leading certain subsidiaries to report separately. The filing is signed by Ashley Grim on 03/27/2026.
National Vision Holdings, Inc. director and Chief Executive Officer Alexander Wilkes reported an open-market sale of 35,000 shares of common stock on March 11, 2026 at a weighted average price of $26.54 per share, in multiple trades between $26.21 and $26.91.
The transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was pre-scheduled. Following this sale, Wilkes directly holds 16,431 shares of National Vision common stock.
EyePoint Pharmaceuticals notified the SEC of a proposed sale of 35,000 shares of Common Stock via Fidelity Brokerage Services LLC, with an aggregate value of $955,500.00, filed on 03/11/2026. The filing lists 34,242 shares from restricted stock vesting (08/19/2025) and 758 shares from an ESPP purchase (11/28/2025). Shares outstanding were 79,437,185 as of 03/11/2026.
National Vision Holdings, Inc. reported that Chief Technology Officer David G. Cutler acquired 10,753 restricted stock units as a grant or award. Each restricted stock unit converts into one share of common stock. Following this grant, he holds 36,750 restricted stock units directly.
According to the disclosure, one-third of these restricted stock units will vest on each anniversary of the grant date, March 6, 2026, aligning compensation with longer-term company performance and retention incentives.